托法替布治疗强直性脊柱炎的研究进展
Progress of Tofacitinib in the Treatment of Ankylosing Spondylitis
DOI: 10.12677/acm.2024.1451673, PDF,   
作者: 杨逸冰：川北医学院临床医学院，四川 南充；李江涛：宜宾市第一人民医院风湿免疫科，四川 宜宾
关键词: 强直性脊柱炎；托法替布；JAK抑制剂；有效性；安全性；Ankylosing Spondylitis； Tofacitinib； Janus Kinase Inhibitors； Efficacy； Security
摘要: 强直性脊柱炎是一种病因不明的慢性炎症性疾病。目前尚缺乏根治的方法，治疗上以非甾体抗炎药、改善病情抗风湿药为主，但疗效不一，部分患者病情仍无法有效控制。随着托法替布在临床的长期应用，其治疗强直性脊柱炎的疗效及安全性已得到了肯定，可能为临床用药提供新的选择。本文将结合最新的临床研究，针对托法替布治疗强直性脊柱炎的作用机制、有效性及安全性评价等方面进行综述，希望为临床用药提供新的选择。
Abstract: Ankylosing spondylitis is a chronic inflammatory disease of unknown etiology. At present, there is still a lack of radical treatment, and the treatment is mainly non-steroidal anti-inflammatory drugs and disease-modifying anti-rheumatic drugs, but the efficacy is different, and the condition of some patients is still not effectively controlled. With the long-term clinical application of tofacitinib, its efficacy and safety in the treatment of ankylosing spondylitis have been affirmed, which may provide a new choice for clinical use. This article will review the mechanism, efficacy and safety evaluation of tofacitinib in the treatment of ankylosing spondylitis in combination with the latest clinical research, hoping to provide new options for clinical use.
文章引用：杨逸冰, 李江涛. 托法替布治疗强直性脊柱炎的研究进展[J]. 临床医学进展, 2024, 14(5): 2221-2228. https://doi.org/10.12677/acm.2024.1451673

参考文献

[1] 范晓云, 李志军. 强直性脊柱炎的诊断与治疗[J]. 中华全科医学, 2020, 18(8): 1256-1257.
[2] Hwang, M.C., Ridley, L. and Reveille, J.D. (2021) Ankylosing Spondylitis Risk Factors: A Systematic Literature Review. Clinical Rheumatology, 40, 3079-3093. [Google Scholar] [CrossRef] [PubMed]
[3] Xi, Y., Jiang, T., Chaurasiya, B., et al. (2019) Advances in Nanomedicine for the Treatment of Ankylosing Spondylitis. International Journal of Nanomedicine, 14, 8521-8542. [Google Scholar] [CrossRef] 
[4] 韩仁芳, 陈梦雅, 刘瑞, 等. 强直性脊柱炎2261例流行特征及功能状态现状分析[J]. 安徽医药, 2017, 21(1): 73-77.
[5] Zhai, J., Rong, J., Li, Q., et al. (2013) Immunogenetic Study in Chinese Population with Ankylosing Spondylitis: Are There Specific Genes Recently Disclosed? Clinical & Developmental Immunology, 2013, Article ID: 419357. [Google Scholar] [CrossRef] [PubMed]
[6] Ward, M.M., Deodhar, A., Gensler, L.S., et al. (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology, 71, 1599-1613. [Google Scholar] [CrossRef] [PubMed]
[7] Deodhar, A., van der Heijde, D., Gensler, L.S., et al. (2020) Ixekizumab for Patients with Non-Radiographic Axial Spondyloarthritis (COAST-X): A Randomised, Placebo-Controlled Trial. The Lancet, 395, 53-64. [Google Scholar] [CrossRef] 
[8] Yin, Y., Wang, M., Liu, M., et al. (2020) Efficacy and Safety of IL-17 Inhibitors for the Treatment of Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials. Arthritis Research & Therapy, 22, Article No. 111. [Google Scholar] [CrossRef] 
[9] Baeten, D., Østergaard, M., Wei, J.C., et al. (2018) Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Dose-Finding Phase 2 Study. Annals of the Rheumatic Diseases, 77, 1295-1302. [Google Scholar] [CrossRef] [PubMed]
[10] Chimenti, M.S., Perricone, C., Conigliaro, P., et al. (2020) Tackling the Autoimmune Side in Spondyloarthritis: A Systematic Review. Autoimmunity Reviews, 19, Article 102648. [Google Scholar] [CrossRef] [PubMed]
[11] Smolen, J.S., Pangan, A.L., Emery, P., et al. (2019) Upadacitinib as Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (SELECT-MONOTHERAPY): A Randomised, Placebo-Controlled, Double-Blind Phase 3 Study. The Lancet, 393, 2303-2311. [Google Scholar] [CrossRef] 
[12] Guttman-Yassky, E., Teixeira, H.D., Simpson, E.L., et al. (2021) Once-Daily Upadacitinib versus Placebo in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis (Measure up 1 and Measure up 2): Results from Two Replicate Double-Blind, Randomised Controlled Phase 3 Trials. The Lancet, 397, 2151-2168. [Google Scholar] [CrossRef] 
[13] Van der Heijde, D., Song, I.H., Pangan, A.L., et al. (2019) Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis (SELECT-AXIS 1): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Trial. The Lancet, 394, 2108-2117. [Google Scholar] [CrossRef] 
[14] Van der Heijde, D., Strand, V., Tanaka, Y., et al. (2019) Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes from a Twenty-Four-Month, Phase III Study. Arthritis & Rheumatology, 71, 878-891. [Google Scholar] [CrossRef] [PubMed]
[15] Campanaro, F., Batticciotto, A., Zaffaroni, A., et al. (2021) JAK Inhibitors and Psoriatic Arthritis: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 20, Article 102902. [Google Scholar] [CrossRef] [PubMed]
[16] Sandborn, W.J., Peyrin-Biroulet, L., Quirk, D., et al. (2022) Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 20, 1821-1830.E3. [Google Scholar] [CrossRef] [PubMed]
[17] Ruperto, N., Brunner, H.I., Synoverska, O., et al. (2021) Tofacitinib in Juvenile Idiopathic Arthritis: A Double-Blind, Placebo-Controlled, Withdrawal Phase 3 Randomised Trial. The Lancet, 398, 1984-1996. [Google Scholar] [CrossRef] 
[18] 《Janus激酶抑制剂治疗风湿免疫病超药品说明书用药中国专家共识》制定专家组. Janus激酶抑制剂治疗风湿免疫病超药品说明书用药中国专家共识[J]. 中华风湿病学杂志, 2023, 27(1): 1-9.
[19] Paroli, M., Caccavale, R., Paroli, M.P., et al. (2023) Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis. International Journal of Molecular Sciences, 24, Article 1027. [Google Scholar] [CrossRef] [PubMed]
[20] Hu, X., Li, J., Fu, M., et al. (2021) The JAK/STAT Signaling Pathway: From Bench to Clinic. Signal Transduction and Targeted Therapy, 6, Article No. 402. [Google Scholar] [CrossRef] [PubMed]
[21] Veale, D.J., McGonagle, D., McInnes, I.B., et al. (2019) The Rationale for Janus Kinase Inhibitors for the Treatment of Spondyloarthritis. Rheumatology, 58, 197-205. [Google Scholar] [CrossRef] [PubMed]
[22] Hammitzsch, A., Lorenz, G. and Moog, P. (2020) Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies. Frontiers in Immunology, 11, Article 591176. [Google Scholar] [CrossRef] [PubMed]
[23] Ritchlin, C. and Adamopoulos, I.E. (2021) Axial Spondyloarthritis: New Advances in Diagnosis and Management. The BMJ, 372, m4447. [Google Scholar] [CrossRef] [PubMed]
[24] Raychaudhuri, S., Cheema, K.S., Raychaudhuri, S.K., et al. (2021) Janus Kinase-Signal Transducers and Activators of Transcription Cell Signaling in Spondyloarthritis: Rationale and Evidence for JAK Inhibition. Current Opinion in Rheumatology, 33, 348-355. [Google Scholar] [CrossRef] 
[25] Fragoulis, G.E., Brock, J., Basu, N., et al. (2021) The Role for JAK Inhibitors in the Treatment of Immune-Mediated Rheumatic and Related Conditions. Journal of Allergy and Clinical Immunology, 148, 941-952. [Google Scholar] [CrossRef] [PubMed]
[26] Van der Heijde, D., Deodhar, A., Wei, J.C., et al. (2017) Tofacitinib in Patients with Ankylosing Spondylitis: A Phase II, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study. Annals of the Rheumatic Diseases, 76, 1325-1326. [Google Scholar] [CrossRef] [PubMed]
[27] Landewe, R., Braun, J., Deodhar, A., et al. (2014) Efficacy of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis Including Ankylosing Spondylitis: 24-Week Results of a Double-Blind Randomised Placebo-Controlled Phase 3 Study. Annals of the Rheumatic Diseases, 73, 39-47. [Google Scholar] [CrossRef] [PubMed]
[28] 徐鹏慧, 屈文龙, 周惠琼. JAK抑制剂托法替布在脊柱关节炎伴外周关节病变治疗中的应用观察(附3例报告) [J]. 山东医药, 2020, 60(32): 60-63.
[29] Deodhar, A., Sliwinska-Stanczyk, P., Xu, H., et al. (2021) Tofacitinib for the Treatment of Ankylosing Spondylitis: A Phase III, Randomised, Double-Blind, Placebo-Controlled Study. Annals of the Rheumatic Diseases, 80, 1004-1013. [Google Scholar] [CrossRef] [PubMed]
[30] Navarro-Compán, V., Wei, J.C., Van den Bosch, F., et al. (2022) Effect of Tofacitinib on Pain, Fatigue, Health-Related Quality of Life and Work Productivity in Patients with Active Ankylosing Spondylitis: Results from a Phase III, Randomised, Double-Blind, Placebo-Controlled Trial. RMD Open, 8, e002253. [Google Scholar] [CrossRef] [PubMed]
[31] 姜克悦, 刘磊, 王文惠. 枸橼酸托法替布治疗活动性强直性脊柱炎的随机对照研究[J]. 实用医学杂志, 2022, 38(11): 1415-1418.
[32] 刘昭诗, 张桂芝, 周佳鑫, 等. 托法替布联合雷公藤多苷治疗难治性强直性脊柱炎继发肾脏淀粉样变一例[J]. 中华临床免疫和变态反应杂志, 2022, 16(5): 488-491.
[33] Wollenhaupt, J., Lee, E.B., Curtis, J.R., et al. (2019) Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 21, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[34] Gialouri, C.G., Moustafa, S., Thomas, K., et al. (2023) Herpes Zoster in Patients with Inflammatory Arthritides or Ulcerative Colitis Treated with Tofacitinib, Baricitinib or Upadacitinib: A Systematic Review of Clinical Trials and Real-World Studies. Rheumatology International, 43, 421-435. [Google Scholar] [CrossRef] [PubMed]
[35] Leng, X., Lin, W., Liu, S., et al. (2023) Efficacy and Safety of Tofacitinib in Chinese Patients with Active Psoriatic Arthritis: A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study. RMD Open, 9, e002559. [Google Scholar] [CrossRef] [PubMed]
[36] Song, G.G. and Lee, Y.H. (2021) Relative Efficacy and Safety of Tofacitinib for Treating Psoriasis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. International Journal of Clinical Pharmacology and Therapeutics, 59, 308-314. [Google Scholar] [CrossRef] 
[37] Alves, C., Penedones, A., Mendes, D., et al. (2023) Topical Janus Kinase Inhibitors in Atopic Dermatitis: A Safety Network Meta-Analysis. International Journal of Clinical Pharmacy, 45, 830-838. [Google Scholar] [CrossRef] [PubMed]
[38] Fenster, M., Alayo, Q.A., Khatiwada, A., et al. (2021) Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study from the TROPIC Consortium. Clinical Gastroenterology and Hepatology, 19, 2207-2209.E3. [Google Scholar] [CrossRef] [PubMed]
[39] Ytterberg, S.R., Bhatt, D.L., Mikuls, T.R., et al. (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. The New England Journal of Medicine, 386, 316-326. [Google Scholar] [CrossRef] 
[40] Ingrassia, J.P., Maqsood, M.H., Gelfand, J.M., et al. (2023) Cardiovascular and Venous Thromboembolic Risk with JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis. JAMA Dermatology, 160, 28-36. [Google Scholar] [CrossRef] [PubMed]

为你推荐